$1.21
6.92% today
Nasdaq, Apr 04, 08:19 pm CET
ISIN
US62818Q1040
Symbol
MBIO
Sector
Industry

Mustang Bio, Inc. Stock price

$1.30
-0.52 28.57% 1M
-9.83 88.31% 6M
-7.55 85.31% YTD
-39.70 96.83% 1Y
-846.20 99.85% 3Y
-1,858.70 99.93% 5Y
-7,348.70 99.98% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.14 9.72%
ISIN
US62818Q1040
Symbol
MBIO
Sector
Industry

Key metrics

Market capitalization $3.58m
Enterprise Value $-2.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.21
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-12.78m
Free Cash Flow (TTM) Free Cash Flow $-11.41m
Cash position $6.84m
EPS (TTM) EPS $-43.66
Short interest 2.31%
Show more

Is Mustang Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Mustang Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Mustang Bio, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Mustang Bio, Inc.:

Buy
100%

Financial data from Mustang Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.17 1.17
49% 49%
-
-1.17 -1.17
49% 49%
-
- Selling and Administrative Expenses 2.73 2.73
61% 61%
-
- Research and Development Expense 7.71 7.71
80% 80%
-
-12 -12
76% 76%
-
- Depreciation and Amortization 1.17 1.17
49% 49%
-
EBIT (Operating Income) EBIT -13 -13
75% 75%
-
Net Profit -16 -16
69% 69%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mustang Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mustang Bio, Inc. Stock News

Neutral
GlobeNewsWire
30 days ago
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1).
Neutral
GlobeNewsWire
about one month ago
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent dives...
Neutral
GlobeNewsWire
about 2 months ago
WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing.
More Mustang Bio, Inc. News

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Head office United States
CEO Manuel Litchman
Employees 6
Founded 2015
Website www.mustangbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today